Abstract
The role of melatonin in glucose homeostasis is an active area of investigation. There is a growing body of evidence suggesting a link between disturbances in melatonin production and impaired insulin, glucose, lipid metabolism, and antioxidant capacity. Furthermore, melatonin has been found to influence insulin secretion both in vivo and in vitro, and night-time melatonin levels are related to night-time insulin concentrations in patients with diabetes. In several recent studies, a single nucleotide polymorphism of the human melatonin receptor 1B has been described as being causally linked to an increased risk of developing type 2 diabetes. Taken together, these data suggest that endogenous as well as exogenous melatonin may play a role in diabetes and associated metabolic disturbances not only by regulating insulin secretion but also by providing protection against reactive oxygen species, considering pancreatic β-cells are particularly susceptible to oxidative stress because they possess only low-antioxidative capacity.
Keywords: Diabetes, glucagon, glucose, insulin, melatonin, melatonin receptors, metabolic syndrome, oxidative stress.
Current Pharmaceutical Design
Title:Melatonin and Glucose Metabolism: Clinical Relevance
Volume: 20 Issue: 30
Author(s): Lardone P.J., Alvarez-Sanchez Sanchez N., Guerrero J.M. and Carrillo-Vico A.
Affiliation:
Keywords: Diabetes, glucagon, glucose, insulin, melatonin, melatonin receptors, metabolic syndrome, oxidative stress.
Abstract: The role of melatonin in glucose homeostasis is an active area of investigation. There is a growing body of evidence suggesting a link between disturbances in melatonin production and impaired insulin, glucose, lipid metabolism, and antioxidant capacity. Furthermore, melatonin has been found to influence insulin secretion both in vivo and in vitro, and night-time melatonin levels are related to night-time insulin concentrations in patients with diabetes. In several recent studies, a single nucleotide polymorphism of the human melatonin receptor 1B has been described as being causally linked to an increased risk of developing type 2 diabetes. Taken together, these data suggest that endogenous as well as exogenous melatonin may play a role in diabetes and associated metabolic disturbances not only by regulating insulin secretion but also by providing protection against reactive oxygen species, considering pancreatic β-cells are particularly susceptible to oxidative stress because they possess only low-antioxidative capacity.
Export Options
About this article
Cite this article as:
P.J. Lardone, Sanchez N. Alvarez-Sanchez, J.M. Guerrero and A. Carrillo-Vico, Melatonin and Glucose Metabolism: Clinical Relevance, Current Pharmaceutical Design 2014; 20 (30) . https://dx.doi.org/10.2174/1381612819666131119101032
DOI https://dx.doi.org/10.2174/1381612819666131119101032 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Challenges for the Treatment of Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Editorial (Thematic Issue: Targeting Cell Death and Proliferation Receptors in Cancer)
Current Pharmaceutical Design Molecular Targets of Diabetic Vascular Complications and Potential New Drugs
Current Drug Targets Therapeutic Applications of Crocus sativus L. (Saffron): A Review
The Natural Products Journal Sleep Apnea: an Underestimated Cause of Resistant Hypertension
Current Hypertension Reviews Managing Obesity in Patients with Mental Illness: A literature Review and Implication for Clinical Practice
Current Psychiatry Reviews Application of Sustained-release Carrier of NanoAg-Epidermal Growth Factor in Promoting Refractory Diabetic Wound Healing
Letters in Drug Design & Discovery Editorial (Oxidative Stress in the Vascular Wall: A Useful Physiological Process or a Therapeutic Target in Vascular Disease?)
Recent Patents on Cardiovascular Drug Discovery Transport of Nucleoside Analogs Across the Plasma Membrane: A Clue to Understanding Drug-Induced Cytotoxicity
Current Drug Metabolism Intracellular Signaling of the Aging Suppressor Protein Klotho
Current Molecular Medicine Biomarkers of Alzheimer's Disease Risk in Peripheral Tissues; Focus on Buccal Cells
Current Alzheimer Research Perspectives on mTOR Inhibitors for Castration-Refractory Prostate Cancer
Current Cancer Drug Targets The Use of Sensory Nerve Stimulation and Compression Bandaging to Improve Sensory Nerve Function and Healing of Chronic Venous Leg Ulcers
Current Aging Science Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Recent Patents on Drug Delivery & Formulation Is the Cerebellum Involved in the Nervous Control of the Immune System Function?
Endocrine, Metabolic & Immune Disorders - Drug Targets MicroRNA-16-5p Aggravates Myocardial Infarction Injury by Targeting the Expression of Insulin Receptor Substrates 1 and Mediating Myocardial Apoptosis and Angiogenesis
Current Neurovascular Research Potential Role for Dendritic Cells in Endothelial Dysfunction, Diabetes and Cardiovascular Disease
Current Pharmaceutical Design CCL2-CCR2 Signaling in Disease Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacogenetics Strategies: From Candidate Genes to Whole-Genome Association Analysis. Exploratory or Confirmatory Studies?
Current Pharmacogenomics and Personalized Medicine Phosphatidylinositol 3-kinase Glu545Lys and His1047Tyr Mutations are not Associated with T2D
Current Diabetes Reviews